IRLAB strengthens its value creation capabilities through extended and expanded debt financing
Gothenburg, February 18, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the duration of the existing loan from Fenja Capital of SEK 55 million has been extended from May 22, 2025, to June 30, 2026, at the latest. Additionally, the loan can be extended by an extra SEK 20 million under certain conditions. At the same time, IRLAB has raised new loans from some of its major shareholders for a total of SEK 22.4 million. This increases the company’s financial resilience in a phase where several potentially value-creating milestones are rapidly approaching.
Read More >Watch IRLAB’s
Capital Markets Day 2023!
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >